A New Preclinical Paradigm for Testing Anti-Aging Therapeutics
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Testing drugs for anti-aging effects has historically been conducted in mouse life-span studies, but are costly and time consuming, and more importantly, difficult to recapitulate in humans. In addition, life-span studies in mice are not well suited to testing drug combinations that target multiple factors involved in aging. Additional paradigms for testing therapeutics aimed at slowing aging are needed. A new paradigm, designated as the Geropathology Grading Platform (GGP), is based on a standardized set of guidelines developed to detect the presence or absence of low-impact histopathological lesions and to determine the level of severity of high-impact lesions in organs from aged mice. The GGP generates a numerical score for each age-related lesion in an organ, summed for total lesions, and averaged over multiple mice to obtain a composite lesion score (CLS). Preliminary studies show that the platform generates CLSs that increase with the age of mice in an organ-dependent manner. The CLSs are sensitive enough to detect changes elicited by interventions that extend mouse life span, and thus help validate the GGP as a novel tool to measure biological aging. While currently optimized for mice, the GGP could be adapted to any preclinical animal model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular pathology endpoints useful for aging studies
Niedernhofer, L. J., Kirkland, J. L., & Ladiges, W. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2016.09.012 · Cited by 59
Self-citation
Cited by
Fisetin is a senotherapeutic that extends health and lifespan
Yousefzadeh, M. J., Zhu, Y., McGowan, S. J., Angelini, L., Fuhrmann-Stroissnigg, H., Xu, M., Ling, Y. Y., Melos, K. I., Pirtskhalava, T., Inman, C. L., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.09.015 · Cited by 1,032
Self-citationCellular senescence: a key therapeutic target in aging and diseases
Zhang, L., Pitcher, L. E., Yousefzadeh, M. J., Niedernhofer, L. J., Robbins, P. D., & Zhu, Y. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158450 · Cited by 631
“The use of the geropathology grading platform to assess aging-specific lesions in tissues is an additional way to evaluate healthspan in a postmortem manner (141, 142).”
MethodSelf-citationZhao, J., Zhang, L., Lu, A., Han, Y., Colangelo, D., Bukata, C., Scibetta, A., Yousefzadeh, M. J., Li, X., Gurkar, A. U., et al. (2020) · Aging · doi:10.18632/aging.102863 · Cited by 122
“There are reduced lymphoid aggregates in the liver and kidney of Ercc1 and Ercc1Atm mice, suggesting reduced inflammatory infiltration in tissues at the age analyzed [54].”
BackgroundSelf-citationHeterochronic parabiosis regulates the extent of cellular senescence in multiple tissues
Yousefzadeh, M. J., Wilkinson, J. E., Hughes, B., Gadela, N., Ladiges, W. C., Vo, N., Niedernhofer, L. J., Huffman, D. M., & Robbins, P. D. (2020) · GeroScience · doi:10.1007/s11357-020-00185-1 · Cited by 70
Self-citationJiang, Z., Wang, J., Imai, D., Snider, T., Klug, J., Mangalindan, R., Morton, J., Zhu, L., Salmon, A. B., Wezeman, J., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-11229-1 · Cited by 21
Self-citation
Metadata
- Authors
- Ladiges, W., Snyder, J. M., Wilkinson, E., Imai, D. M., Snider, T., Ge, X., Ciol, M., Pettan-Brewer, C., Pillai, S. P. S., Morton, J., Quarles, E., Rabinovitch, P., Niedernhofer, L., & Liggitt, D.
- Venue
- The Journals of Gerontology: Series A
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-02-22
- Volume
- 72
- Issue
- 6
- Pages
- 760-762
- ISSN
- 1079-5006 (ISSN-L)
- 1758-535X
- OpenAlex
- W2589668141
- Cited by
- 31
- References
- 1
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A New Preclinical Paradigm for Testing Anti-Aging Therapeutics. https://app.cochat.ai/papers/10.1093/gerona/glx019
- The paper
- Ladiges, W., Snyder, J. M., Wilkinson, E., Imai, D. M., Snider, T., Ge, X., Ciol, M., Pettan-Brewer, C., Pillai, S. P. S., Morton, J., Quarles, E., Rabinovitch, P., Niedernhofer, L., & Liggitt, D. (2017). A New Preclinical Paradigm for Testing Anti-Aging Therapeutics. The Journals of Gerontology: Series A. https://doi.org/10.1093/gerona/glx019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.